Request Trial
shutterstock_761246722_casimiro_pt
Casimiro PT / Shutterstock.com
6 October 2020Biotech

Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to  President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Regeneron and Amgen call a truce on two Eylea biosimilar patents
28 October 2026   Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.
Biotech
10x and Parse set to end sequencing feud after appeals court defeat
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
Biotech
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
16 October 2026   All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
In-house counsel rethink patent filing strategies as costs mount
Fenwick hires NY partner to advise on regulatory matters
UK unveils £1bn sector investment push after recent setbacks
Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos
Oura targets Ultrahuman’s redesigned smart ring following import ban
Weil collapse leaves IP talent facing uncertain future after major expansion